Intellia Therapeutics (NTLA) Common Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Common Equity data on file, last reported at $620.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $620.9 million, down 20.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $620.9 million (down 20.38% YoY), and the FY2025 annual result was $671.4 million, down 23.0% from the prior year.
• Common Equity fell to $620.9 million in Q1 2026 per NTLA's latest filing, from $671.4 million in the prior quarter.
• Over five years, Common Equity peaked at $1.2 billion in Q4 2022 and troughed at $620.9 million in Q1 2026.
• A 5-year average of $920.9 million and a median of $953.8 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 77.96% in 2022, then retreated 26.34% in 2025.
• A 5-year view of Common Equity shows it stood at $1.2 billion in 2022, then declined by 15.01% to $1.1 billion in 2023, then slipped by 16.97% to $872.0 million in 2024, then retreated by 23.0% to $671.4 million in 2025, then dropped by 7.51% to $620.9 million in 2026.
• Business Quant data shows NTLA's Common Equity at $620.9 million in Q1 2026, $671.4 million in Q4 2025, and $748.4 million in Q3 2025.